Myomar Molecular develops a urine-based diagnostic test that assesses muscle mass and muscle health to help monitor degenerative disease and senior wellness. Clinics across Canada are already using its tests, and the company has begun selling in the U.S. while partnering with Suntory Wellness to support growth in Japan; it also has partners in Singapore and South Korea. Myomar recently opened a centralized lab in Aurora, Colorado to facilitate U.S. sample analysis and simplify cross-border shipping. The company has started formal marketing campaigns and is onboarding major clinics in Canada and the U.S., contributing to a reported doubling of sales in the most recent quarter. Its team comprises eight staff and two full-time contractors, and it plans to finalize an at-home strip test by 2026 as part of its product roadmap.

Total raised

$4M

Funding rounds

4

Latest round

Seed

Latest activity

May 2026